Search Results
Your search for all items matches 35151 pages
Showing 1 - 50Real-World Data Show COVID-19 Boosters Offer Protection for Patients With Cancer
COVID-19 vaccine boosters for adult patients with cancer helped to keep these patients from being hospitalized or admitted to intensive care units due to severe COVID-19 infections, according to the results of a retrospective cohort study published in JAMA Oncology. “Cancer patients are a...
Outcomes Support CAR T-Cell Therapy Use in Elderly Patients With B-Cell Lymphomas
Patients in their 80s or older with B-cell lymphomas are able to receive chimeric antigen receptor (CAR) T-cell therapy safely, results of a multicenter retrospective study published in Bone Marrow Transplantation showed. These patients are usually not eligible for clinical trials of CAR T-cell...
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
As reported in JAMA Network Open by Mamtani et al, a retrospective cohort study of patients with metastatic urothelial cancer showed population-level increases in survival after the introduction of novel cancer therapeutics—immune checkpoint inhibitors (ie, pembrolizumab and atezolizumab) and...
Thyroidectomy Without Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer
In a UK phase III trial (IoN) reported in The Lancet, Mallick et al compared survival outcomes among patients with low-risk differentiated thyroid cancer who underwent thyroidectomy with no postoperative radioiodine ablation vs thyroidectomy plus ablation. Study Details In the multicenter...
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
In an analysis from the French SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Taïeb et al examined survival outcomes associated with a change in ctDNA from baseline to 1 month after start of treatment in patients receiving ICI treatment with avelumab for deficient mismatch repair/microsatellite...
Classifying Pancreatic Cysts Using AI Models
In a proof-of-concept study published in the Journal of the American College of Surgeons, researchers investigated whether artificial intelligence (AI) models such as ChatGPT-4 can be used to accurately extract and classify diagnostic data from radiologic imaging reports of pancreatic cysts. The...
Study Links Childhood Proximity to Radiation-Contaminated Coldwater Creek With Elevated Cancer Odds
Living near Coldwater Creek in St. Louis, Missouri, during childhood was found to be associated with an increased risk of overall cancer, according to the findings of a study published in JAMA Network Open. “Our research indicates that the communities around North St. Louis appear to have had...
Studies Explore Cardiac Risks and Clinical Characteristics Associated With Immune Checkpoint Inhibitor–Related Myocarditis
Immune checkpoint inhibitors (ICIs) have significantly impacted treatment options for a wide range of cancers given their efficacy, especially among cancer types that are considered immunologically “hot.” With this broad benefit across many tumor types, researchers continue to look for ways to...
Survey Highlights Top Anxiety Points for Caregivers After a Cancer Diagnosis
New survey findings highlight that the anxiety caused by a cancer diagnosis extends far beyond just the patient diagnosed. The emotional impact is shared by caregivers and loved ones, with stress, grief, and worry over treatments, pain, and life expectancy weighing heavily on these individuals,...
Risk of Liver Cancer With Oral Contraceptive Use
In a UK population-based study reported in The Lancet Oncology, Watling et al examined the relationship between ever use vs never use of oral contraceptives and the risk of liver cancer. Some findings suggested the possibility of slightly increased risk with longer-term use. As noted by the...
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes?
Aprepitant, a commonly used antiemetic, led to improvements in patient outcomes when given during chemotherapy treatment for patients with non-luminal early breast cancer. Patients showed better prognoses and survival advantages, particularly among those with triple-negative breast cancer. Study...
Lisocabtagene Maraleucel as Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up
As reported in the Journal of Clinical Oncology by Kamdar et al, the 3-year follow-up of the phase III TRANSFORM trial showed that lisocabtagene maraleucel (liso-cel) maintained superior efficacy vs standard of care (SOC) in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL). ...
Online AI Tool Offers Rapid, Accurate Diagnosis for Endocrine Cancers
Researchers have developed a novel AI-powered online platform for diagnosing endocrine cancers with speed and accuracy. The AI models achieved diagnostic accuracy of 99% or more in recognizing multiple endocrine tumors. Reports of the development and validation of the models were presented at ENDO...
People With Acromegaly Face Elevated Cancer Risk, Study Finds
A new study presented at the 2025 Annual Meeting of the Endocrine Society (ENDO 2025) found that individuals with acromegaly—an endocrine disorder caused by excessive growth hormone secretion—are at a significantly heightened risk of developing various types of cancer, often at younger ages...
New Guidelines on Comprehensive Biomarker Testing of Bronchoscopic Biopsies
Linear endobronchial guided sampling of accessible mediastinal lesions is well established as a first-choice modality for lung cancer mediastinal staging. Parenchymal lung lesions, however, are routinely accessed by either a percutaneous (CT-guided) or a bronchoscopic approach. There have been few...
Teclistamab for High-Risk, Heavily Pretreated Multiple Myeloma: Real-World Data
Teclistamab-cqyv is the first bispecific T-cell engager antibody that targets both B-cell maturation antigen (BCMA) proteins on myeloma cells and CD3 proteins on T cells. It was approved by the U.S. Food and Drug Administration in 2022 for treatment of patients with relapsed or refractory multiple...
Phase II Trial Supports SRT as Alternative to WBRT in SCLC
Patients with small cell lung cancer (SCLC) that has metastasized to the brain were safely and successfully treated with targeted stereotactic radiation (SRT) rather than whole-brain radiation therapy (WBRT) in a phase II trial, demonstrating the practicality of a less-invasive approach for...
Metformin in Metastatic Prostate Cancer
In a phase III trial (part of the STAMPEDE platform) reported in The Lancet Oncology, Gillessen et al investigated the survival outcomes of adding metformin to standard of care (SOC) in nondiabetic patients with metastatic hormone-sensitive prostate cancer starting androgen-deprivation therapy...
Outcomes With Perioperative Immunotherapy in Resectable NSCLC
In a retrospective cohort study reported in JAMA Network Open, Desai et al examined survival outcomes with the addition of immunotherapy to neoadjuvant or adjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC). Study Details The study involved data from the Flatiron...
Sharp Rise in Obesity-Linked Cancer Mortality Highlights Geographic and Demographic Gaps
Obesity-related cancer deaths have tripled in the United States over the past 2 decades, with significant disparities seen by gender, race, age, and geography, according to findings from a national epidemiological analysis presented at ENDO 2025, the annual meeting of The Endocrine Society...
Case 3: Newly Diagnosed Limited-Stage Small Cell Lung Cancer
This is Part 3 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss treatment of newly diagnosed limited-stage small cell ...
Case 2: Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
This is Part 2 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of newly diagnosed extensive-stage...
Case 1: Relapsed Small Cell Lung Cancer
This is Part 1 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of relapsed small cell lung cancer...
Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer
The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or long-term quality of life, although the study failed to meet its primary endpoint of overall...
Four-Year Outcomes Highlight Efficacy of Neoadjuvant Nivolumab and Relatlimab in Advanced Resectable Melanoma
A neoadjuvant and adjuvant regimen of anti–PD-1 therapy with nivolumab and anti–LAG-3 therapy with relatlimab led to a 4-year event-free survival rate of 80% in patients with advanced, resectable melanoma, according to long-term findings from a phase II study published in the Journal of Clinical...
Surgery vs Ablation in Small Hepatocellular Carcinoma
In two Japanese studies (SURF-RCT and SURF-Cohort) reported in the Journal of Clinical Oncology, Kawaguchi et al compared the outcomes of surgery vs radiofrequency ablation (RFA) in patients with small hepatocellular carcinoma (HCC). Study Details Two multicenter studies were performed, with...
New Research Offers Reassurance About Localized Prostate Cancer Prognosis
A recent study out of Sweden found that people diagnosed with nonmetastatic low-risk prostate cancer later in life were 90% more likely to survive their cancer for their remaining life expectancy if they were treated according to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Of...
Chemoimmunotherapy for Advanced BTC: 3-Year Overall Survival Update From the TOPAZ Trial
In a follow-up analysis of the pivotal TOPAZ-1 study, which established the combination of the PD-L1 inhibitor durvalumab plus gemcitabine and cisplatin as the first-line treatment for advanced biliary tract cancer (BTC), researchers have shown that after 3 years, more than twice as many study...
RP1 Plus Nivolumab in Anti–PD-1–Resistant Advanced Melanoma
When combined with nivolumab, RP1 (vusolimogene oderparepvec), a genetically engineered herpes simplex virus type 1–based oncolytic immunotherapy, induced deep and durable systemic responses in patients with advanced melanoma who have failed to respond to prior anti–PD-1 therapy, according to...
Literature Review Highlights Rising Incidence and Disparities in Many Early-Onset GI Cancers
Rates of early-onset gastrointestinal cancers, beyond just colorectal cancer, are rising among people younger than age 50, according to experts from Dana-Farber Cancer Institute. Researchers from Dana-Farber published a literature review in the British Journal of Surgery showing that cases of newly ...
A Young Hematologist’s Take on ICML 2025
From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an innovative chemotherapy-free approach to treating lymphoma)—the nostalgia at the International...
AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging
An update of staging guidelines from the American Joint Committee on Cancer (AJCC) for human papillomavirus (HPV)-positive throat cancer—now more common in the United States than cervical cancer, according to the American Cancer Society—aims to make treatment of early-stage disease more consistent...
Ruxolitinib for Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease
In the 3-year final analysis of the phase III REACH3 trial reported in the Journal of Clinical Oncology, Zeiser et al compared the use of ruxolitinib vs best available therapy (BAT) in terms of failure-free survival and duration of response in patients with steroid-refractory or -dependent chronic...
Women Over the Age of 65 Still at Heightened Risk of HPV-Related Cervical Cancer
Women aged 65 years and older are still at a heightened risk of cervical cancer caused by human papillomavirus (HPV), suggest the findings of a large observational Chinese study published by Ye et al in Gynecology and Obstetrics Clinical Medicine. Most guidelines currently recommend discontinuing...
Corticosteroids May Limit Efficacy of Immunotherapy in Patients With NSCLC
Corticosteroids, which are commonly prescribed to alleviate cancer-related symptoms in patients with non–small cell lung cancer (NSCLC) treated with immunotherapy, may be the reason certain immunotherapies fail in treating the disease, according to new research published by Polyakov et al in Cancer ...
The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies
Over the past 20 years, increased understanding of the biological mechanism of disease has led to improved treatment options for all malignancies. Within each disease subtype, we have molecularly characterized tumors and developed specific treatment algorithms to optimize patient outcomes. Among...
Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk
Treating drinking water for multiple contaminants, especially arsenic and chromium-6, could prevent more than 50,000 cancer cases in the United States, according to the results of a study by the Environmental Working Group that was published in Environmental Research. Study findings highlighted...
Subsequent Neoplasm Risk Among Childhood Cancer Survivors: Effect of BMI and Physical Activity
In a study reported in JAMA Oncology, Joffe et al examined the association of high body mass index (BMI) and low physical activity with increased risk of subsequent neoplasms among childhood cancer survivors. Study Details The study involved data on 5-year survivors of childhood cancers diagnosed...
Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma
In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD (doxorubicin, vinblastine, dacarbazine; N-AVD) vs brentuximab vedotin plus AVD (BV-AVD) in patients with advanced-stage...
Adult Survivors of Childhood Cancer May Be at Increased Risk of Severe COVID-19 Infection
People who have survived cancer as children may be at a higher risk of developing severe COVID-19 infection—even decades after their cancer diagnosis, according to results published by Louro et al in The Lancet Regional Health – Europe. Thanks to medical advances, more and more children are...
Can Planned C-Sections Increase the Risk of Childhood ALL?
Children born by planned cesarean section (C-section) may have an increased risk of developing acute lymphoblastic leukemia (ALL) later in life, according to a recent study published by Kampitsi et al in the International Journal of Cancer. Alhough the researchers did find an association, they...
BMI and Cardiovascular Disease Associated With Increased Breast Cancer Risk
Weight-associated risk for developing breast cancer after menopause may be higher among women with cardiovascular disease compared with those without cardiovascular disease and women with or without type 2 diabetes, according to the results of two prospective European cohort studies, which were...
Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma
In a phase II trial reported in The Lancet Oncology, Elimova et al evaluated the efficacy and safety of the bispecific monoclonal antibody zanidatamab plus chemotherapy in the first-line treatment of patients with advanced HER2-positive gastroesophageal adenocarcinoma. Study Details In the trial,...
Survey Finds Confusion Over Mammogram Guidelines
Mammograms can detect breast cancer early before symptoms appear, and regular screening decreases the risk of dying from breast cancer. But a recent survey conducted by the Annenberg Public Policy Center (APPC) of the University of Pennsylvania shows that some Americans appear to be confused about...
Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC
The U.S. Food and Drug Administration (FDA) has approved SIR-Spheres Y-90 resin microspheres, manufactured by Sirtex, for the treatment of unresectable hepatocellular carcinoma (HCC). With this approval, these microspheres become the only radioembolization therapy approved for the treatment of both ...
Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma
In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic,...
Survival Disparities Rise in Patients With Advanced Cancer Depending on Whether They Have Insurance to Cover Immune Checkpoint Inhibitors
A study led by researchers at the American Cancer Society examining the association between the introduction of immune checkpoint inhibitors (ICIs) and changes in survival disparities by health insurance coverage among patients with newly diagnosed stage IV melanoma, non–small cell lung cancer...
Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies
Investigators have bioengineered an organotypic immunocompetent chip—a laboratory device that combines the physical structure of human leukemia bone marrow and a functioning immune system—to empower real-time spatiotemporal monitoring of CAR-T cell functionality for leukemias. The preclinical...
Air Pollution Linked to Distinct Genomic Signatures in Lung Cancers Among Never-Smokers
A large analysis of the mutational processes of lung cancers in never-smoker patients showed that exposure to fine-particulate air pollution was strongly associated with increased genomic changes, including in cancer-driving and cancer-promoting genetic mutations. Findings from the whole-genome...
FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sunvozertinib (Zegfrovy), a selective EGFR tyrosine kinase inhibitor, for adults with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an...
